News Center

Company news

Media reports

03

2026-11

Completion of Long-term Safety Clinical Trial of KX-826 Tincture 1.0% For The Treatment of Male Adult AGA in China

Suzhou, 3 November, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term safety clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of androgenetic alopecia has completed follow-up visits for the subjects, demonstrating favorable safety.

Picture Name

21

2026-10

Receipt of Notice of Grant of Invention Patent For KT-939

Suzhou, 21 October, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Group received a notice of grant of invention patent issued by the China National Intellectual Property Administration in respect of KT-939 (Chinese trade name 欧希美多®KT-939, English trade name OXIMIDOL®KT-939), a novel and highly effective tyrosinase inhibitor developed in-house by the Group for inhibiting melanin production. The patent relates to a tyrosinase inhibitor and uses thereof (application No. 202580002670.3).

Picture Name

07

2026-09

Successful Completion of Long-Term Human Safety Trial Of KT-939

Suzhou, 7 September, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term human safety trial of KT-939, an in-house developed novel and highly effective tyrosinase inhibitor for inhibiting melanin production, was successfully completed on 4 September 2026. A total of 114 subjects received continuous administration of KT-939 for 52 consecutive weeks, and preliminary data indicate that none of them experienced any adverse skin reactions, in line with the 28 week interim clinical results, fully demonstrating the excellent safety profile of KT-939.

Picture Name

24

2026-08

Research findings of MYC/GSPT1 protein degrader GT19630 have been published in Blood, a top international journal in hematology

Suzhou, 24 August, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that a collaborative research paper with The University of Texas MD Anderson Cancer Center was published on August 17, 2026, in Blood, a premier journal in the field of international hematology. The findings demonstrate that GT19630, a novel MYC/GSPT1 degrader independently developed by Kintor, offers a promising therapeutic strategy for MYC-driven hematological malignancies.

Picture Name

01

2026-06

Kx-826 Phase III Clinical Trial And Combination Therapy Study Data For Aga Presented At The 2026 World Congress For Hair Research (Wchr 2026), And Was Selected As An Outstanding Poster

Suzhou, 1 June, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed and potential first-in-class KX-826 data from two important clinical studies was presented at the 14th World Congress for Hair Research (WCHR 2026) held in Seoul, South Korea from May 28 to 31, 2026.

Picture Name

18

2026-03

Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint

Suzhou, 18 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase III Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results.

Picture Name
< 1234...25 > proceed page

Kintor